Skip to main navigation Skip to search Skip to main content

SPR001-205 A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Exploratory Pharmacodynamics of SPR001 (Tildacerfont) in Children Aged 6 to 17 Years with Congenital Adrenal Hyperplasia

Project: Research

Project Details

StatusActive
Effective start/end date01/6/22 → 01/9/27

Funding

  • Spruce Biosciences Incorporated: $64,333.02